Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
  • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
  • C07C237/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/60—Salicylic acid; Derivatives thereof
  • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
  • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
  • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
  • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the present invention relates to compounds for use in the treatment of diseases resulting from pathologic inflammation. More particularly, the invention relates to 4-alkanoylaminobenzamide derivatives for use in combination with 5-aminosalicylate (5-ASA) agents in the treatment of inflammatory bowel disease (IBD). Furthermore, the invention relates to combinations of 4- alkanoylaminobenzamide derivatives and 5-ASA agents and to pharmaceutical formulations and kit-of-parts comprising such combinations.
• 5-ASA 5-aminosalicylate
• IBD Crohn's disease
• UC ulcerative colitis
• CD Crohn's disease
• UC patients can be classified as having 1 ) ulcerative proctitis involving only the rectum, 2) left sided UC involving the colorectum distal to the splenic flexure and 3) extensive UC involving the colon proximal to the splenic flexure (includes pancolitis).
• Symptoms may vary depending on the degree and extent of inflammation. Patients are classified as having mild, moderate or severe disease activity according to one or more measures of disease severity. The hallmark symptom of UC is bloody diarrhoea accompanied by urgency to defecate. Other symptoms include crampy abdominal pain, loss of appetite, fatigue, weight loss and fevers.
• CD and UC account for substantial costs to the health care system and society.
• UC ulcerative colitis
• Current medications are moderately efficacious, and adverse effects are a problem. It is therefore urgent to improve clinical management by establishing new treatment strategies.
• the therapeutic goals are induction and maintenance of remission and prevention of complications. Patients with mucosal healing who have no or very mild signs and symptoms are considered in remission.
• the ultimate treatment goal for all patients with UC is steroid-free clinical and endoscopic remission. Effect on the inflammatory process is essential since lack of control of inflammation even in the presence of control of symptoms is correlated with poor long term outcome.
• the risk of colectomy and colorectal cancer is increased in patients who fail to respond to medical management.
• Extra- intestinal manifestations of UC include primary sclerosing cholangitis, as well as joint, skin and eye manifestations.
• First-line therapy in mild to moderate UC includes administration of the 5- aminosalicylate (5-ASA; mesalazine [CAS No. 89-57-6]) agents.
• Sulfasalazine (SASP [CAS No. 599-79-1]) an azo-bonded prodrug of 5-ASA, is the parent 5-ASA agent.
• SASP provides a modest benefit for the treatment of mild to moderately active CD (Lim, 2016).
• Patients who are failing or do not respond fully to 5-ASA drugs can be treated with corticosteroids or immunomodulators
• Tumour necrosis factor-alpha (TNFa) blockers are indicated for the treatment of UC patients with moderately to severely active UC, and who have failed conventional therapies.
• 5-ASA agents The mainstay of therapy for mild to moderate UC is 5-ASA agents (Hanauer, 2004). The successful management of UC was greatly facilitated after the introduction of SASP (Svartz 1942). It is generally considered that 5-ASA represents the therapeutically active moiety of SASP (Azad Khan 1977; van Hees 1980). Orally ingested SASP is enzymatically split in the colon into 5-ASA and sulfapyridine (CAS No. 144-83-2) (Peppercorn 1972), thus releasing 5-ASA acting locally on the colonic mucosa.
• Other azo-bonded 5-ASA agents include olsalazine (CAS No. 15722-48-2) and balsalazide (CAS No. 80573-04-2).
• 5-ASA delivery systems use for example pH-dependent delayed-release formulations to liberate the 5-ASA in sufficient concentrations directly in the colon (Amidon 2015). Both oral and rectal therapies are effective in inducing and maintaining remission. Once daily is the optimal dosing and there is marginal evidence for a significant dose-response effect above 2400 mg/day.
• 5-ASA agents The mechanism of action exerted by 5-ASA agents remains unclear, but a central mechanism that explains the inhibitory effects of 5-ASA on multiple pathways of inflammation may be due to its inhibition of nuclear factor kappa B (NFKB) activation (MacDermott, 2000).
• NFKB nuclear factor kappa B
• SASP has been shown to be a potent inhibitor of N FKB activation, able to suppress NFKB dependent transcription, and able to prevent nuclear translocation of NFKB due to inhibition of inhibitory kBa (IkBa)
• 5-ASA has been demonstrated to inhibit TNFa stimulated NFKB activation, NFKB nuclear translocation, and degradation of IkBa (Kaiser, 1999).
• N FKB is considered to be a heterodimer of proteins that belong to the Rel family of transcription factors (TF).
• TF transcription factors
• a common feature of the regulation of TFs belonging to the Rel family is their sequestration in the cytoplasm as inactive complexes with a class of inhibitory molecules known as I KBS.
• I KBS inhibitory molecules
• Treatment of cells with different inducers, e.g., TNFa results in the dissociation of the cytoplasmic complexes and translocation of free N FKB to the nucleus.
• inducers e.g., TNFa
• N FKB a transient phase mediated through IkBa
• IkBb a persistent phase mediated through IkBb.
• the distinct behaviour of the two I KBS following stimulation fulfils the promise of differential regulation suggested by the existence of multiple I KB isoforms.
• the two major I KB isoforms interact with the same Rel proteins, they are activated by distinct signaling pathways, probably eliciting very different physiological responses. While the IkBa response is used for responding immediately to transient situations of stress, the persistent response through IkBb may be utilized for situations of chronic inflammation, infection, stress, or differentiation (Thompson, 1995).
• the 4-aminobenzamides including metoclopramide (CAS No. 364-62-5) and procainamide (CAS No. 51-06-9) constitute a class of compounds that have been developed for a number of clinical indications and screened or used as antiemetics, antiarrhythmics, local anaesthetics,
• Declopramide was listed amongst a number of small molecule NFKB inhibitors as a potential therapeutic agent for the treatment of autoimmune diseases, including IBD (Ivanenkov, 2011 ).
• Combined 5-ASA and procainamide were used in an attempt to improve the anticolitis efficacy of 5-ASA. Rectal administration of combined 5-ASA and procainamide elicited an additive anticolitis effect in the 2,4,6-trinitrobenzenesulfonic acid-induced rat colitis model (Kim, 2016).
• rectal administration of combined 5-ASA and procainamide nor oral administration of 5-ASA azo-bonded to procainamide (5-ASA-azo-PA) did show superiority to oral SASP alone.
• U.S. Pat. No. 3,177,252 discloses 4-alkanoylaminobenzamides for the treatment of emesis, and behaviour disturbances.
• WO 99/63987 discloses 4-acetamido-3-chloro-N-[2- (diethylamino)ethyl]benzamide (N-acetyldeclopramide; hereinafter Cpd A) and uses thereof for inhibiting or killing tumour or cancer cells and as a potential therapeutic agent for treating inflammatory disorders.
• N-Acetylprocainamide acecainide, CAS No. 32795-44-1
• the 4-aminobenzamides are known to inhibit NFKB, and these compounds were also found to induce apoptosis (Liberg, 1999). Acetylation of declopramide, giving Cpd A, obliterates the induction of apoptosis (Liberg 1999; Lindgren 2003), notwithstanding, markedly enhancing the NFKB inhibition compared to the corresponding 4-aminobenzamide (Liberg, 1999; Lindgren, 2001 ). While 4-aminobenzamides inhibit IkBa breakdown and the NFKB rescue pathway, the 4- alkanoylaminobenzamide analogues inhibit IkBb breakdown and do not affect the NFKB rescue pathway (Lindgren, 2003).
• One aspect is a compound of formula (I)
• Ri is selected from C1 -C6 alkyl and C3-C6 cycloalkyl
• R 2 is selected from H and C1 -C3 alkyl
• R 3 , R 4 , Rs, and R 6 are independently selected from hydrogen, C1 -C3 alkyl, C1 -C3 alkoxy, C1 -C3 alkylthio, halogen, phenyl and benzyl, wherein any alkyl is optionally substituted with one or more fluoro;
• R 7 is selected from hydrogen and C1 -C3 alkyl
• R 8 and R 9 are independently selected from C1 -C6 alkyl, or
• r is 0 or 1 ;
• R-io is selected from C1 -C3 alkyl and C3-C4 cycloalkyl; said alkyl and cycloalkyl optionally being substituted with hydroxy, halogen, cyano, COOR12, or NHR 13 ;
• Q is selected from CHRu, NRn and O;
• R11 is selected from hydrogen, C1 -C3 alkyl and C3-C4 cycloalkyl; said alkyl and cycloalkyl optionally being substituted with hydroxy, halogen, cyano, COOR12, or NHR 13 ; R12 and R13 are independently selected from hydrogen, C1 -C3 alkyl and C3-C4 cycloalkyl;
• p is 1 , 2, or 3 when Q is CHRu;
• p is 2 or 3 when Q is selected from NR-H and O;
• a 5-ASA agent for use in combination with a 5-ASA agent, in the treatment of a disease resulting from pathologic inflammation.
• One aspect is a combination of:
• Ri is selected from C1 -C6 alkyl and C3-C6 cycloalkyl
• R 2 is selected from H and C1 -C3 alkyl
• R 3 , R 4 , Rs, and R 6 are independently selected from hydrogen, C1 -C3 alkyl, C1 -C3 alkoxy, C1 -C3 alkylthio, halogen, phenyl and benzyl, wherein any alkyl is optionally substituted with one or more fluoro;
• R 7 is selected from hydrogen and C1 -C3 alkyl
• R 8 and R 9 are independently selected from C1 -C6 alkyl, or
• r is 0 or 1 ;
• R-io is selected from C1 -C3 alkyl and C3-C4 cycloalkyl; said alkyl and cycloalkyl optionally being substituted with hydroxy, halogen, cyano, COOR12, or NHR 13 ;
• Q is selected from CHRu, NRn and O;
• R11 is selected from hydrogen, C1 -C3 alkyl and C3-C4 cycloalkyl; said alkyl and cycloalkyl optionally being substituted with hydroxy, halogen, cyano, COOR12, or NHR 13 ;
• R12 and RI 3 are independently selected from hydrogen, C1 -C3 alkyl and C3-C4 cycloalkyl;
• p is 1 , 2, or 3 when Q is CHRu;
• p is 2 or 3 when Q is selected from N R-H and O;
• a further aspect is a pharmaceutical composition
• a pharmaceutical composition comprising a combination as defined herein, and optionally a pharmaceutically acceptable excipient.
• the composition is useful for the treatment of pathologic inflammation, and in particular for the treatment of IBD.
• kits-of-parts comprising a combination as defined herein, wherein each one of components (i) and (ii) is optionally formulated in admixture with a pharmaceutically acceptable excipient.
• the kit-of-parts is useful for the treatment of pathologic inflammation, and in particular for the treatment of IBD.
• Still a further aspect is the use of a compound of formula (I) as defined herein, or a salt or solvate thereof, in the manufacturing of a medicament for use in the treatment of a disease resulting from pathologic inflammation, wherein the treatment further comprises administration of a 5-ASA agent.
• Still a further aspect is the use of a compound of formula (I) as defined herein, or a salt or solvate thereof, in the manufacturing of a medicament for use in the treatment of a disease resulting from pathologic inflammation, wherein the medicament further comprises a 5-ASA agent.
• Still a further aspect is the use of a compound of formula (I), or a salt or solvate thereof, and of a 5- ASA agent in the manufacturing of a kit-of-parts for use in the treatment of pathologic inflammation, e.g. IBD.
• a further aspect is a method for the treatment of a disease resulting from pathologic inflammation, comprising administering a therapeutically effective amount of a compound of formula (I), or a salt or solvate thereof, to a mammal in need of such treatment, in combination with administration of a 5-ASA agent to the mammal.
• Cn alkyl refers to a linear or branched chain saturated hydrocarbyl radical containing n carbon atoms in the chain, i.e. a moiety of formula C n H 2n+i .
• Cn-Cm alkyl refers to a linear or branched chain alkyl radical containing a number of carbon atoms in the chain ranging from n to m, wherein n and m are both integers and m is higher than n.
• Cn cycloalkyl refers to a cyclic hydrocarbyl radical of formula C n H 2n -i ⁇
• Cn-Cm cycloalkyl refers to a cyclic hydrocarbyl radical containing a number of carbon atoms in the cycle ranging from n to m, wherein n and m are both integers and m is higher than n.
• R is Cn-Cm alkyl.
• methoxy is C1 alkoxy.
• Cn-Cm alkylthio refers to a moiety of formula
• R is Cn-Cm alkyl.
• methylthio is C1 alkylthio.
• halogen refers to F, Cl, Br or I; preferably F, Cl or Br.
• phenyl refers to a radical of formula
• benzyl refers to a radical of formula
• AABZ means a compound of formula (I) as described herein. Unless otherwise indicated or apparent from the context, the term also includes a pharmaceutically acceptable salt or solvate (including hydrate) thereof.
• “about” in the context of a numerical value or range means ⁇ 20% of the numerical value or range recited or claimed.
• “add-on” or“add-on therapy” means an assemblage of reagents for use in therapy, wherein the subject receiving the therapy begins a first treatment regimen of one or more reagents prior to beginning a second treatment regimen of one or more different reagents in addition to the first treatment regimen, so that not all of the reagents used in the therapy are started at the same time.
• “administration”,“administering” etc. means the giving of, dispensing of, or application of medicines, drugs, or remedies to a subject (e.g. a mammal subject, preferably a human) to relieve or cure a pathological condition.
• Oral administration is one way of administering the instant compounds to the subject.
• an“amount” or“dose” of a compound refers to the milligrams of the compound present in a preparation, regardless of the form of the preparation.
• A“dose of 5.0 mg of a compound” means the amount of compound in a preparation is 5.0 mg, regardless of the form of the preparation.
• the weight of the salt form necessary to provide a dose of 5.0 mg of the free base compound would be greater than 5.0 mg due to the presence of the additional acid.
• the term”5-ASA agent means a compound containing the 5-aminosalicylic acid moiety.
• the term also includes a salt or solvate of the compound, unless otherwise specified or apparent from the context.
• “combination” means an assemblage of compounds for use in therapy either by simultaneous or separate (e.g. sequential or concomitant) administration. Simultaneous
• administration refers to administration of an admixture (whether a true mixture, a suspension, an emulsion or other physical combination) of two active ingredients (e.g. the AABZ and the 5-ASA agent).
• the combination may be an admixture of the AABZ and the 5-ASA agent; or the AABZ and the 5-ASA agent may be provided in separate containers and combined just prior to administration. Separate administration may be sequential (i.e. consecutive) or concomitant (i.e. happening at the same time).
• Separate administration refers to the concomitant or sequential administration of the AABZ and the 5-ASA agent as separate formulations, but at the same time or at times sufficiently close together for an activity to be observed that is at least additive, relative to the activity of either one of the AABZ and the 5-ASA agent alone.
• “CD” means Crohn's disease.
• “Cpd A” means 4-acetamido-3-chloro-N-[2-(diethylamino)ethyl]benzamide (N- acetyldeclopramide) hydochloride.
• DSS Dextran Sulfate Sodium
• an amount of an AABZ or of a 5-ASA agent refers to the amount that is sufficient to yield a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response), commensurate with a reasonable benefit/risk ratio when used in the manner of this invention.
• excipient is a substance formulated alongside the active ingredient of a medication included for such purposes as long-term stabilization, to provide bulk to a solid formulation, to act as a carrier and/or diluent, to confer a therapeutic enhancement on the active ingredient in the final dosage form, e.g. by facilitating absorption, reducing viscosity, or enhancing solubility.
• An excipient can also be useful in the manufacturing process, e.g. by facilitating powder flowability or providing non-stick properties. Examples of excipients are antiadherents, binders, coatings, colours, disintegrants, flavours, glidants, lubricants, preservatives, sorbents, sweeteners, and vehicles (carriers).
• a disease resulting from pathologic inflammation refers to diseases such as inflammatory bowel disease, rheumatic diseases, autoimmune diseases and disorders, and further, such diseases where inflammation plays a major role such as Alzheimer ' s disease, atherosclerosis and stroke. More particularly, as used herein,“a disease resulting from pathologic inflammation” refers to diseases and disorders selected from the group consisting of ulcerative colitis, Crohn's disease, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriasis, multiple sclerosis, and type I diabetes, and in particular to diseases selected from the group consisting of ulcerative colitis and Crohn's disease.
• IBD means inflammatory bowel disease
• “inhibition” of disease progression or disease complication in a subject means preventing or reducing the disease progression and/or disease complication in the subject.
• NFKB nuclear factor kappa B.
• ⁇ kB means inhibitor of kappa B.
• pharmaceutically acceptable refers to that which is suitable for use with humans and/or animals, generally safe and non-toxic at normal use, i.e. without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
• SASP means sulfasalazine
• a“salt thereof” is a salt of the instant compounds which have been modified by making acid or base salts of the compounds.
• pharmaceutically acceptable salt refers to the relatively non-toxic, inorganic and organic acid or base addition salts of compounds of the present invention.
• one means of preparing such a salt is by treating a compound of the present invention with an inorganic acid.
• solvate means a physical association of a compound (e.g. a compound of formula (I)) with one or more solvent molecules, e.g. by hydrogen bonding.
• solvent molecules e.g. by hydrogen bonding.
• solvent molecules e.g. by hydrogen bonding.
• solvates encompasses both solution-phase and isolable solvates.
• Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are generally known to the person of ordinary skill in the art.
• a“subject afflicted with a disease resulting from pathologic inflammation” means a subject who was been clinically diagnosed to have such a disease.
• a“symptom” associated with a disease resulting from pathologic inflammation includes any clinical or laboratory manifestation associated with the disease and is not limited to what the subject can feel or observe.
• TF means transcription factor
• tumour necrosis factor means tumour necrosis factor
• tumour necrosis factor alpha tumour necrosis factor alpha
• treating encompasses, e.g., inducing inhibition, regression, or stasis of a disease or disorder, e.g., IBD, or alleviating, lessening, suppressing, inhibiting, reducing the severity of, eliminating or substantially eliminating, or ameliorating a symptom of the disease or disorder.
• UC ulcerative colitis
• the IBDs including UC and CD are chronic, relapsing, and remitting conditions without a definitive cure.
• Current medications are moderately efficacious for induction and maintenance of clinical and endoscopic remission, and adverse effects are a problem.
• not all IBD patients respond adequately to currently available disease-modifying drugs.
• An important objective of the present invention is to provide a new medicament and method for the treatment of a disease resulting from pathologic inflammation, e.g. IBD, with the final aim of changing the disease course.
• a more effective treatment of e.g. such diseases involves not just N FKB inhibition, but the use of NFKB inhibitors that in combination are capable of exerting a dual action on the NFKB activity.
• NFKB inhibitors that together simultaneously inhibit the degradation of the two major forms of the IKB proteins, i.e., IkBa and IkBb, a treatment superior to the existing therapy with 5-ASA alone is attainable.
• the inventors unexpectedly and surprisingly found that combining a compound of formula (I) with a greater than minimal effective amount of a 5-ASA agent as defined herein above results in a synergistically enhanced therapeutic effect, with a favourable safety profile.
• one further aspect is an AABZ for use in combination with a 5-ASA agent, in the treatment of a disorder (a disease resulting from pathologic inflammation, e.g. IBD), which disorder is associated with (e.g. mediated by) N FKB activity.
• a further aspect is an AABZ for use in combination with a 5-ASA agent, to inhibit NFKB activity in a mammalian (e.g. human) cell, for the treatment of a disorder (a disease resulting from pathologic inflammation, e.g. IBD) associated with (e.g. mediated by) N FKB activity.
• a further aspect is an AABZ, for use in combination with a 5-ASA agent, to inhibit the degradation of IkBa and IkBb in a cell, for the treatment of a disorder (a disease resulting from pathologic inflammation, e.g. IBD) associated with (e.g. mediated by) NFKB activity in the cell.
• a further aspect is a method for the treatment of a disorder (a disease resulting from pathologic inflammation, e.g. IBD associated with (e.g. mediated by) NFKB activity, comprising administering a therapeutically effective amount of an AABZ in combination with a therapeutically effective amount of a 5-ASA agent, to a mammal in need of such treatment.
• R-i is selected from C1-C6 alkyl and C3-C6 cycloalkyl.
• Ri is selected from C1-C5 alkyl and C3-C5 cycloalkyl, e.g. from C1-C4 alkyl and C3-C4 cycloalkyl, or from C1-C3 alkyl and C3 cycloalkyl.
• Ri is selected from C1-C6 alkyl, e.g. from C1-C5 alkyl or from C1-C4 alkyl or from C1-C3 alkyl, or from C1-C2 alkyl.
• Ri is selected from methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, cyclobutyl, n-pentyl, sec-pentyl, iso-pentyl, tert- pentyl, neo-pentyl, and cyclopentyl; e.g.
• Ri is selected from methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, sec-pentyl, iso-pentyl, tert-pentyl, and neo-pentyl.
• Ri is selected from methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, and cyclobutyl, e.g.
• Ri is selected from methyl, ethyl, n-propyl, iso-propyl, and cyclopropyl, e.g. from methyl, ethyl, n-propyl, and iso- propyl.
• Ri is selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec- butyl, iso-butyl, tert-butyl, n-pentyl, sec-pentyl, iso-pentyl, tert-pentyl, and neo-pentyl; e.g. from methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, and tert-butyl; or from methyl, ethyl, n-propyl, and iso-propyl; e.g.
• Ri is methyl or ethyl. In some embodiments, Ri is methyl. In some embodiments, Ri is ethyl. In some embodiments, Ri is iso-propyl.
• R 2 is selected from hydrogen and C1 -C3 alkyl. In some embodiments, R 2 is selected from hydrogen, methyl, ethyl, n-propyl and iso-propyl; e.g. from hydrogen, methyl and ethyl; or from hydrogen and methyl. In some embodiments, R 2 is hydrogen.
• the moieties R 3 , R 4 , R 5 , and R 6 are independently selected from hydrogen, C1 -C3 alkyl, C1 -C3 alkoxy, C1 -C3 alkylthio, halogen, phenyl and benzyl, wherein any alkyl is optionally substituted with one or more fluoro.
• R 3 , R 4 , R 5 , and R 6 are independently selected from hydrogen, C1 -C3 alkyl, C1 -C3 alkoxy, C1 -C3 alkylthio, and halogen, wherein any alkyl is optionally substituted with one or more fluoro.
• R 3 , R , R 5 , and R 6 are independently selected from hydrogen, C1 -C3 alkyl, C1 -C3 alkoxy, and halogen, wherein any alkyl is optionally substituted with one or more fluoro.
• R 3 , R , R 5 , and R 6 are independently selected from hydrogen, C1 -C3 alkyl, C1 -C3 alkoxy, and halogen, wherein any alkyl is optionally substituted with one or more fluoro.
• R 3 , R , R 5 , and R 6 are independently selected from hydrogen, C1 -C3 alkyl and halogen, wherein any alkyl is optionally substituted with one or more fluoro.
• R 3 , R , R 5 , and R 6 are independently selected from hydrogen, C1 -C3 alkoxy and halogen, wherein any alkyl is optionally substituted with one or more fluoro.
• R 3 , R , R 5 , and R 6 are independently selected from hydrogen, C1 -C3 alkoxy, C1 -C3 alkylthio, and halogen, wherein any alkyl is optionally substituted with one or more fluoro.
• R 3 , R , R 5 , and R 6 are independently selected from hydrogen and halogen.
• any one of R 3 , R 4 , R 5 , and R 6 is selected from C1 -C3 alkyl, it e.g. may be selected from methyl and ethyl; in particular it may be methyl.
• R 3 , R 4 , R 5 , and R 6 is selected from C1 -C3 alkoxy, it e.g. may be selected from methoxy and ethoxy; in particular it may be methoxy.
• R 3 , R , R 5 , and R 6 is selected from C1 -C3 alkylthio, it e.g. may be selected from methylthio and ethylthio; in particular it may be methylthio.
• halogen e.g. may be selected from fluoro, chloro and bromo; in particular said halogen may be chloro or bromo, e.g. chloro.
• said halogen more particularly is selected from fluoro and chloro.
• R 3 , R , R 5 , and R 6 are independently selected from hydrogen, methyl, ethyl, methoxy, ethoxy, methylthio, fluoro, chloro, bromo, trifluoromethyl, phenyl and benzyl, e.g. from hydrogen, methyl, ethyl, methoxy, ethoxy, methylthio, fluoro, chloro, bromo, and trifluoromethyl; or from hydrogen, methyl, ethyl, methoxy, ethoxy, fluoro, chloro, bromo, and trifluoromethyl; e.g.
• At least one, more preferably at least two of R 3 , R , R 5 , and R 6 are hydrogen. In some of the above embodiments, two of R 3 , R , R 5 , and R 6 are hydrogen. In some of the above embodiments, three of R 3 , R , R 5 , and R 6 are hydrogen. In some of the above embodiments, each one of R 3 , R , R 5 , and R 6 is hydrogen. In some of the above embodiments, at least one of R 3 , R , R 5 , and R 6 is different from hydrogen. In some of the above embodiments, one of R 3 , R , R 5 , and R 6 is different from hydrogen and the three others are hydrogen; e.g.
• R 3 is halogen, such as chloro; and the three others are hydrogen.
• R 3 is different from hydrogen, and each one of R , R 5 , and R 6 is hydrogen.
• R 5 is different from hydrogen, and each one of R 3 , R , and R 6 is hydrogen.
• one of R 3 , R , R 5 , and R 6 is fluoro, chloro, or bromo, in particular chloro; and the three others are hydrogen.
• R 3 is hydrogen or halogen, hydrogen and chloro; and R , R 5 , and R 6 are hydrogen.
• R , and R 6 are hydrogen; e.g. R and R 6 are hydrogen and at least one of R 3 and R 5 is different from hydrogen, e.g. both R 3 and R 5 are different from hydrogen.
• R 4 and R 5 are hydrogen; e.g. R 4 and R 5 are hydrogen and at least one of R 3 and R 6 is different from hydrogen, e.g. both R 3 and R 6 are different from hydrogen.
• R 3 and R 4 are hydrogen; e.g. R 3 and R are hydrogen and at least one of R 5 and R 6 is different from hydrogen, e.g. both R 5 and R 6 are different from hydrogen. In some of the above embodiments, R 5 and R 6 are not methoxy or ethoxy.
• R 7 is selected from hydrogen and C1 -C3 alkyl. In some embodiments, R 7 is selected from hydrogen, methyl, ethyl, propyl and iso-propyl; e.g. from hydrogen, methyl, ethyl, and propyl.
• R 7 is selected from hydrogen, methyl, and ethyl. In some embodiments, R 7 is selected from hydrogen and methyl. In some embodiments, R 7 is hydrogen.
• the moieties R 8 and R 9 are independently selected from C1 -C6 alkyl, or R 8 and R 9 together with the nitrogen atom to which they are both attach form a moiety of formula (II) as defined herein.
• R 8 and R 9 are independently selected from C1 -C6 alkyl.
• R 8 and R 9 for example may be selected from C1 -C5 alkyl; or from C1 -C4 alkyl; or from C1 -C3 alkyl; e.g. from methyl and ethyl.
• R 8 and R 9 when R 8 and R 9 are selected from C1 -C6 alkyl, both R 8 and R 9 are ethyl.
• R 8 and R 9 together with the nitrogen atom to which they are both attached form a moiety of formula (II) as defined herein, in which case the compound of formula (I) may be represented by formula (la)
• RrR 7 , R-io, Q, p and r are as defined herein.
• r is 0 or 1. In some embodiments, r is 0. In some embodiments, r is 1.
• R 10 is selected from C1 -C3 alkyl and C3-C4 cycloalkyl; said alkyl and cycloalkyl optionally being substituted with hydroxy, halogen, cyano, COOR12, or NHR 13 .
• R10 is selected from methyl, ethyl and cyclopropyl, said methyl, ethyl and
• R10 is selected from C1 -C3 alkyl and C3-C4 cycloalkyl optionally substituted with hydroxy, halogen, and cyano; e.g. with halogen, such as fluoro.
• R10 is selected from C1 -C3 alkyl and C3-C4 cycloalkyl, e.g. methyl, ethyl, and cyclopropyl, e.g. methyl.
• Q is selected from CHR-H , NR-H and O. In some embodiments, Q is selected from CHRu and NR- H . In some embodiments, Q is selected from CHRu and O. In some embodiments,
• Q is CHRu. In some other embodiments, Q is selected from NR- H and O.
• Rn is selected from hydrogen, C1-C3 alkyl and C3-C4 cycloalkyl; said alkyl and cycloalkyl optionally being substituted with hydroxy, halogen, cyano, COOR12, or NHR 13 .
• Rn is selected from hydrogen, methyl, ethyl and cyclopropyl, said methyl, ethyl and cyclopropyl optionally being substituted with hydroxy, halogen, cyano, COOR12, or NHR 13 .
• Rn is selected from hydrogen, C1-C3 alkyl and C3-C4 cycloalkyl, said alkyl and cycloalkyl optionally being substituted with hydroxy, halogen, or cyano; e.g. halogen, such as fluoro.
• Rn is selected hydrogen, C1-C3 alkyl and C3-C4 cycloalkyl, e.g. hydrogen, methyl, ethyl, and cyclopropyl, or hydrogen, methyl and ethyl; in particular hydrogen and methyl.
• Rn is hydrogen.
• Rn is as defined herein above, but is different from hydrogen.
• Rn is C1-C3 alkyl or C3-C4 cycloalkyl substituted with hydroxy, halogen, cyano, COOR12, or NHR 13
• the number of such substituents may be one or more, e.g. 1-3, or 1-2, or 1.
• the moiety R 12 is selected from hydrogen, C1-C3 alkyl and C3-C4 cycloalkyl. In some
• R12 is selected from hydrogen, methyl, ethyl, n-propyl, iso-propyl and cyclopropyl, e.g. from hydrogen, methyl, ethyl, n-propyl, and iso-propyl; or from hydrogen, methyl and ethyl, e.g. from hydrogen and methyl.
• R12 is selected from hydrogen, C1-C3 alkyl and C3-C4 cycloalkyl.
• R12 is selected from C1-C3 alkyl and C3-C4 cycloalkyl, e.g.
• R12 is methyl. In some other embodiments, R12 is hydrogen.
• R 13 is selected from hydrogen, C1-C3 alkyl and C3-C4 cycloalkyl. In some
• R I3 is selected from hydrogen, methyl, ethyl, n-propyl, iso-propyl and cyclopropyl, e.g. from hydrogen, methyl, ethyl, n-propyl, and iso-propyl; or from hydrogen, methyl and ethyl, e.g. from hydrogen and methyl.
• R I3 is selected from hydrogen, C1-C3 alkyl and C3-C4 cycloalkyl.
• R I3 is selected from C1-C3 alkyl and C3-C4 cycloalkyl, e.g.
• R I3 is methyl. In some other embodiments, R I3 is hydrogen.
• p is 1 , 2, or 3 when Q is CHRu; and p is 2 or 3 when Q is selected from NRn and O. In some embodiments, p is 2 or 3. In some embodiments, p is 2. In some embodiments, Q is CHRu and p is 1 or 2. In some embodiments, Q is CHRu, and p is 2. In some other embodiments, Q is CHRu, and p is 1.
• Ri is C1 -C6 alkyl
• R 2 is hydrogen
• R 7 is hydrogen
• R 8 and R 9 are independently selected from C1 -C6 alkyl, or R 8 and R 9 together with the nitrogen atom to which they are both attached form a moiety of formula (II) as defined herein
• R 10 is C1 -C3 alkyl
• Q is CHR-H
• Rn is selected from hydrogen and C1 -C3 alkyl.
• Ri a C1 -C6 alkyl
• R 2 is hydrogen
• R 7 is hydrogen
• R 8 and R 9 are independently selected from C1 -C6 alkyl.
• R-i, R 8 and R 9 are independently selected from C1 -C3 alkyl.
• Ri is C1 -C3 alkyl; R 2 , R 4 , R 5 and R 7 are hydrogen; and R 8 and R 9 are independently selected from C1 -C3 alkyl. In some of these embodiments, Ri is selected from methyl, ethyl and iso-propyl; and R 8 and R 9 are the same or different and selected from methyl, ethyl and n-propyl.
• Ri is selected from methyl, ethyl and iso-propyl; R 2 , R 4 , R 5 , R 6 , and R 7 are hydrogen; and R 8 and R 9 are the same or different and selected from methyl, ethyl and n- propyl.
• R 2 is selected from hydrogen and methyl; R 3 , R 4 , R 5 , and R 6 are
• R 7 is hydrogen; and R 8 and R 9 are the same or different and selected from methyl, ethyl and n-propyl.
• Ri is selected from methyl, ethyl and iso-propyl; R 2 is hydrogen or methyl; R 3 is chloro or hydrogen; R 4 , R 5 , R 6 , and R 7 are hydrogen; and R 8 and R 9 are the same or different and are selected from methyl, ethyl and n-propyl.
• Ri is selected from methyl, ethyl and iso-propyl; R 2 is hydrogen or methyl; R 3 is chloro or hydrogen; R 4 , R 5 , R 6 , and R 7 are hydrogen; and R 8 and R 9 are ethyl.
• Ri is selected from methyl, ethyl and iso-propyl;
• R 2 is hydrogen;
• R 3 is chloro or hydrogen;
• R 4 , R 5 , R 6 , and R 7 are hydrogen;
• R 8 and R 9 are the same or different and are selected from methyl, ethyl and n- propyl.
• Ri is selected from methyl, ethyl and iso-propyl;
• R 2 is hydrogen;
• R 3 is chloro;
• R , R 5 , R 6 , and R 7 are hydrogen; and
• R 8 and R 9 are the same or different and are selected from methyl, ethyl and n-propyl.
• the compound of formula (I) is selected from: 4-acetamido-3-chloro-N-[2-(diethylamino)ethyl]benzamide,
• the compound of formula (I) is selected from
• the compound of formula (I) is 4-acetamido-3-chloro-N-[2- (diethylamino)ethyl]benzamide. In some embodiments, the compound of formula (I) is 4- propanamido-3-chloro-N-[2-(diethylamino)ethyl]benzamide. In some embodiments, the compound of formula (I) is 4-isobutanamido-3-chloro-N-[2-(diethylamino)ethyl]benzamide. In some embodiments, the compound of formula (I) is 4-acetamido-N-[2-(diethylamino)ethyl]benzamide.
• the compound of formula (I) is N-[2-(diethylamino)ethyl]-4- (propanamido)benzamide. In some embodiments, the compound of formula (I) is N-[2- (diethylamino)ethyl]-4-(isobutanamido)benzamide.
• the AABZ is a hydrochloride of a compound of formula (I), e.g. a hydrochloride of any of the above listed compounds of formula (I), e.g. the AABZ is
• the compounds of formula (I) may easily be prepared by the person of ordinary skill in the art, e.g. by following the general procedures as disclosed in US Patent Application No. 2011/0027179, and WO 2005/025498.
• a compound of formula (I) may be preparaed by a method comprising two consecutive nucleophilic substitution reactions as presented by the following reaction scheme.
• compound 1 where R a is e.g. C1 -C3 alkyl, is reacted with compound 2, where L is a suitable leaving group, e.g. Cl, to obtain compound 3.
• L is a suitable leaving group, e.g. Cl
• Compound 3 is subsequently reacted with the secondary amine 4 in the presence of ammonium chloride as a catalyst for the reaction, to obtain the compound of formula (I) as defined herein.
• the compound of formula (I) may optionally be transformed to a suitable pharmaceutically acceptable salt or solvate, e.g. a hydrochloride salt.
• the 5-ASA agent e.g. C1 -C3 alkyl
• 5-ASA agents examples are mesalazine, sulfasalazine, olsalazine or balsalazide (which may also be referred to as balsalazine), or pharmaceutically acceptable salts thereof.
• Table 2 structural formulas of some 5-ASA agents are shown. Table 2
• the 5-ASA agent is mesalazine, sulfasalazine, olsalazine or balsalazide, or a pharmaceutically acceptable salt or solvate of any of these compounds.
• the invention is not limited to these compounds. Rather, any prodrug of 5-ASA or formulation capable of releasing 5-ASA or a salt or solvate thereof in vivo is contemplated as useful according to the invention.
• the 5-ASA agent is mesalazine or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the 5-ASA agent is sulfasalazine or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the 5-ASA agent is olsalazine or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the 5-ASA agent is balsalazide or a pharmaceutically acceptable salt or solvate thereof.
• the 5-ASA agent is a colon-specific prodrug of 5-ASA designed to achieve colonic delivery.
• prodrugs comprise a carrier moiety attached to 5-ASA via the carboxylic or hydroxyl functional group of 5-ASA.
• colon-specific prodrugs of 5-ASA esters and amides have been reported (Amidon, 2015), and any such prodrug is contemplated as useful herein.
• the 5-ASA agent is a colon-specific prodrug fulfilling such criteria for a colon- specific delivery.
• 5-ASA prodrugs useful herein are disclosed e.g. in US Patent No. 7,157,444 and in Jung (1998) and Jung (2003); e.g. 5-aminosalicyl-glycine and 5-aminosalicyl-taurine.
• the 5-ASA agent is a formulation capable of releasing 5-ASA or a salt or solvate thereof, or capable of releasing a 5-ASA prodrug, in vivo, e.g. in the colon.
• the 5-ASA agent is a formulation capable of delayed release of 5-ASA or a salt thereof, e.g. a hydrochloride salt, in the colon.
• the AABZ may be provided as a pharmaceutically acceptable salt of a compound of formula (I), e.g. an acid addition salt.
• the 5-ASA agent may be provided as a pharmaceutically acceptable salt, e.g. a base addition salt.
• acid or base addition salts preferably such acids or bases are used which form suitably therapeutically acceptable salts.
• acids examples include hydrohalogen acids, sulfuric acid, phosphoric acid, nitric acid, aliphatic, alicyclic, aromatic or heterocyclic carboxylic or sulfonic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, p-hydroxybenzoic acid, embonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, halogenbenzenesulfonic acid, toluenesulfonic acid or naphthalenesulfonic acid.
• hydrohalogen acids such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid,
• Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like, and organic bases such as alkoxides, alkyl amides, alkyl and aryl amines, and the like.
• bases useful in preparing salts of the present invention include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, and the like.
• the compound of formula (I) is provided as a hydrochloride.
• the 5-ASA agent is provided as salt of a strong base, e.g. an alkali metal salt, such as a sodium salt.
• solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates.
• the solvate is a hydrate.
• One aspect is a compound of formula (I) as defined herein, or a pharmaceutically acceptable salt or solvate thereof (an AABZ), for use in combination with a 5-ASA agent, in the treatment of a disease resulting from pathologic inflammation.
• an AABZ a pharmaceutically acceptable salt or solvate thereof
• the treatment comprises administering to a subject (a mammal patient, e.g. a human patient) an amount of an AABZ, and a greater than minimal effective amount of a 5-ASA agent, wherein the amounts when taken together are effective to treat the subject.
• a subject a mammal patient, e.g. a human patient
• the total amount of the AABZ and the 5-ASA agent when administered together to treat a subject produces an overall better effect, i.e., a synergistic effect, than the simple sum of effects produced when either component, at the same total amount, is administered alone.
• the treatment comprises administering to a subject (a mammal patient, e.g. a human patient) an AABZ as an add-on therapy or in combination with a 5-ASA agent in treating a subject afflicted with pathological inflammation, an IBD (e.g. UC or CD).
• a subject a mammal patient, e.g. a human patient
• an AABZ as an add-on therapy or in combination with a 5-ASA agent in treating a subject afflicted with pathological inflammation, an IBD (e.g. UC or CD).
• IBD e.g. UC or CD
• the treatment provides induction and maintenance of clinical and endoscopic remission in patients with mild to moderate to severe disease activity.
• the treatment is intended for a patient in remission in order to prevent disease relapse.
• the AABZ is a pharmaceutically acceptable salt of a compound of formula (I), in particular a hydrochloride salt.
• the AABZ is administered via oral administration. In some embodiments, the AABZ is administered in a preferably solid unit formulation, which more preferably is a tablet. In some embodiments, the amount of the AABZ administered is 0.1-25 mg/kg (mg of drug per kg of body weight of subject) per day (any weight value being based on the non-salt, non-solvate form). In other embodiments, the administered amount of the AABZ is 0.3-10 mg/kg per day.
• the amount of the AABZ administered is 5.0-2000 mg/day, or 10-1000 mg/day.
• the AABZ is administered daily, e.g. once daily. In other embodiments, the AABZ is administered twice daily. In other embodiments, the AABZ is administered three times daily. In yet other embodiments, the AABZ is administered four times daily.
• the 5-ASA agent is administered via oral administration. In yet other embodiments, the 5-ASA agent is administered via rectal administration.
• the 5-ASA agent is administered daily. In some embodiments, the amount of the 5-ASA agent administered is 250 mg/day to 8000 mg/day (any weight value being based on the non-salt, non-solvate form). In some embodiments, the amount of the 5-ASA agent
• the amount of the 5-ASA agent administered is less than 8000 mg/day. In other embodiments, the amount of the 5-ASA agent administered is less than 6750 mg/day. In other embodiments, the amount of the 5-ASA agent administered is less than 4000 mg/day. In other embodiments, the amount of the 5-ASA agent administered is less than 2000 mg/day.
• the 5-ASA agent is administered once daily. In other embodiments, the 5- ASA agent is administered twice daily. In other embodiments, the 5-ASA agent is administered three times daily. In yet other embodiments, the 5-ASA agent is administered four times daily.
• the amount of the AABZ and the amount of the 5-ASA agent when taken together preferably are effective to alleviate a symptom of pathologic inflammation, such as IBD, in the subject.
• Symptoms vary depending on the severity of inflammation and may range from mild to severe. Signs and symptoms that are common to both CD and UC include diarrhoea and urgency, fever and fatigue, abdominal pain and cramping, blood in the stool and reduced appetite. Symptoms of an autoimmune disease vary with the disease.
• the administration of the 5-ASA agent substantially precedes the administration of the AABZ, i.e. the subject is receiving therapy by administration of the 5-ASA agent prior to initiating therapy by administration of the AABZ.
• the subject is receiving therapy by administration of the 5-ASA agent for at least 6 months prior to initiating therapy by administration of the AABZ.
• the subject is receiving therapy by administration of the 5-ASA agent for at least 12 months prior to initiating therapy by administration of the AABZ.
• the subject is receiving therapy by administration of the 5-ASA agent for at least 24 months prior to initiating therapy by administration of the AABZ.
• the treatment comprises administration of at least one further drug, e.g. selected from nonsteroidal antiinflammatory drugs (NSAIDs), corticosteroids, cytotoxic drugs, immunosuppressive drugs and antibodies.
• NSAIDs nonsteroidal antiinflammatory drugs
• corticosteroids e.g., corticosteroids
• cytotoxic drugs e.g., cytotoxic drugs, immunosuppressive drugs and antibodies.
• the administration of the AABZ and the 5-ASA agent continues for at least 2 weeks. In other embodiments, the administration of the AABZ and the 5-ASA agent continues for 3 months or more. In yet other embodiments, the administration of theAABZ and the 5-ASA agent continues for 12 months or more.
• the AABZ and the 5-ASA agent are administered in combination with each other (simultaneously, or separately and concomitantly or sequentially) at the molar ratio of the AABZ to the 5-ASA ranging from 1 :100 to 100:1 , e.g. from 1 :50 to 50:1 , or from 1 :20 to 20:1 , or from 1 :10 to 10:1 , or from 1 :5 to 5:1 , or from 1 :2 to 2:1 , e.g. about 1 :1.
• pharmaceutically acceptable salt thereof such as the hydrochloride salt, and sulfasalazine, or a or pharmaceutically acceptable salt thereof, such as a sodium salt, are administered in combination with each other.
• the AABZ can be administered in admixture with suitable pharmaceutical diluents, extenders, or carriers, or any other pharmaceutically acceptable excipients, suitably selected with respect to the intended form of administration and as consistent with conventional pharmaceutical practices.
• a preferred dosage unit will be in a form suitable for oral administration.
• the AABZ can be administered alone but is generally mixed with a pharmaceutically acceptable carrier, and co- administered in the form of a tablet or capsule, liposome, or as an agglomerated powder.
• suitable solid carriers include lactose, sucrose, gelatine and agar. Capsule or tablets can be easily formulated and can be made easy to swallow or chew; other solid forms include granules, and bulk powders.
• Tablets may contain suitable binders, lubricants, disintegrating agents, colouring agents, flavouring agents, flow-inducing agents, and melting agents.
• the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, gelatine, agar, starch, sucrose, glucose, methyl cellulose, dicalcium phosphate, calcium sulphate, mannitol, sorbitol, microcrystalline cellulose and the like.
• Suitable binders include starch, gelatine, natural sugars such as glucose or beta-lactose, corn starch, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, povidone, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
• Lubricants used in these dosage forms include sodium oleate, sodium stearate, sodium benzoate, sodium acetate, sodium chloride, stearic acid, sodium stearyl fumarate, talc and the like.
• Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, croscarmellose sodium, sodium starch glycolate and the like.
• a further aspect is an AABZ for use as an add-on therapy or in combination with a 5-ASA agent in treating a subject afflicted with pathologic inflammation such as IBD.
• a further aspect is a 5-ASA agent for use in the treatment of a subject afflicted with pathologic inflammation such as IBD, by administering to the subject the 5-ASA agent and the AABZ.
• the subject that is treated according to the present invention is a mammal, including a human and a non-human mammal (an animal).
• a mammal including a human and a non-human mammal (an animal).
• non-human mammals are primates,
• the subject is a human.
• the subject is a non-human mammal, e.g. a dog or a horse.
• the disease treated according to the present invention is a disease resulting from pathologic inflammation, as defined herein.
• the disease is IBD.
• the disease is UC.
• the disease is CD.
• CD may affect any part of the gastrointestinal tract.
• the CD is affecting the colon.
• kits-of-parts comprising a combination of an AABZ and a 5-ASA agent, wherein each one of components the AABZ and the 5-ASA agent is optionally formulated in admixture with a pharmaceutically acceptable excipient, such as a carrier.
• a kit-of-parts comprising: a) a first pharmaceutical composition comprising an amount of an AABZ and a pharmaceutically acceptable carrier; b) a second pharmaceutical composition comprising an amount of a 5-ASA agent and a pharmaceutically acceptable carrier; and c) instructions for use of the first and the second pharmaceutical compositions together; e.g. for use in the treatment of IBD.
• the pharmaceutical composition is a mixture of:
• One aspect is a pharmaceutical composition
• a pharmaceutical composition comprising an amount of an AABZ, an amount of a 5- ASA agent, and optionally (but preferably) at least one pharmaceutically acceptable excipient, such as a carrier.
• the pharmaceutical composition is for use in treating a subject afflicted with IBD.
• a suitable pharmaceutical composition is one as described herein above, in connection with a pharmaceutical formulation of an AABZ, but in addition to an AABZ, the composition also contains a 5-ASA agent.
• the AABZ is a pharmaceutically acceptable salt of a compound of formula (I), e.g. a hydrochloride.
• the amount of AABZ in the composition is 5-500 mg (any amount is based on the compound of formula (I) in non-salt form and non-solvated form). In other embodiments, the amount of AABZ is 10-100 mg. In other embodiments, the amount of AABZ is 5-25 mg. In one embodiment, the amount of AABZ in the composition is 500 mg. In other embodiments, the amount of AABZ is 25 mg. In other embodiments, the amount of AABZ is 100 mg. In other embodiments, the amount of AABZ is 10 mg. In other embodiments, the amount of AABZ is less than 10 mg.
• the amount of 5-ASA agent in the composition is 225-1200 mg (any amount is based on the compound of formula (I) in non-salt form and non-solvated form). In other embodiments, the amount of 5-ASA agent is 500-1000 mg. In other embodiments, the amount of 5- ASA agent is 225-450 mg. In one embodiment, the amount of 5-ASA agent in the composition is 750 mg.
• the molar ratio of the AABZ to the 5-ASA in the pharmaceutical composition ranges from 1 :100 to 100:1 , e.g. from 1 :50 to 50:1 , or from 1 :20 to 20:1 , or from 1 :10 to 10:1 , or from 1 :5 to 5:1 , or from 1 :2 to 2:1 , e.g. it may be about 1 :1.
• the total amount of the AABZ and the 5-ASA agent is between 0.1 and 95% by weight of the formulation, e.g. between 0.5 and 50% by weight, or between 1 and 20% by weight, the remainder comprising e.g. a carrier and any other excipient.
• the pharmaceutical composition comprises 4-acetamido-3-chloro-N-[2- (diethylamino)ethyl]benzamide or pharmaceutically acceptable salt thereof, such as the
• hydrochloride salt and sulfasalazine, or a pharmaceutically acceptable salt thereof, such as a sodium salt.
• UC is an inflammatory disease characterized by the infiltration of inflammatory cells, such as macrophages, into the lesioned colon. Macrophages serve a critical role in the initiation and propagation of inflammatory responses by releasing proinflammatory mediators, such as TNF-a.
• Lipopolysaccharide (LPS) is a potent initiator of an inflammatory response.
• LPS Lipopolysaccharide
• NF-kB signaling is activated to regulate the transcription of numerous genes involved in immunity and inflammation to produce proinflammatory cytokines, such as TNF-a.
• Suppression of LPS- induced TNF-a production in RAW264.7 macrophages treated with AABZ was investigated by evaluation of the generation of TNF-a. The aim of this study was to evaluate the anti-inflammatory activity of AABZ.
• DSS dextran sulphate sodium
• TNBS trinitrobenzene sulfonic acid
• the RAW264.7 macrophage line was maintained in DMEM supplemented with 5% FBS at 37°C in a 5% C02-humidified air environment.
• the RAW264.7 cells were seeded in 96-well plates at a density of 1 x105/ml and a volume of 200 mI/well. The cells were incubated for 24 h in medium supplemented with 10% FBS and were then pre-incubated with or without the indicated
• mice The experiment was performed using 6-8-week-old female Balb/c mice after a one-week acclimatization period.
• the mice weighed 18-25 g, were purchased from Taconic (Denmark) and were maintained in a temperature and light-controlled facility with free access to standard rodent chow and water. Mice were randomized to the respective groups five days before start of treatment and were kept 5 to 6 animals per cage.
• SASP (from Sigma-Aldrich, Sweden) was first dissolved in 0.2 M sodium hydroxide (NaOH) at a concentration higher than the required final concentration. Phosphate buffered saline (PBS) was added to the desired concentration and the pH was adjusted to 7.5-8.0 with NaOH or hydrochloric acid. SASP remained completely dissolved at this pH. Cpd A hydrochloride was dissolved in PBS to the desired concentration.
• NaOH sodium hydroxide
• PBS Phosphate buffered saline
• DAI Disease activity index
• Peppercorn MA et al. J Pharmacol Exp Ther. 1972 181 :555-62.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Rheumatology (AREA)
• Pain & Pain Management (AREA)
• Transplantation (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=63294023

Family Applications (1)

Country Status (10)

Cited By (1)

Families Citing this family (1)

Citations (8)

Family Cites Families (3)

• 2019
  • 2019-08-15 WO PCT/EP2019/071903 patent/WO2020035554A1/en not_active Ceased
  • 2019-08-15 CA CA3108361A patent/CA3108361A1/en active Pending
  • 2019-08-15 EP EP19750131.5A patent/EP3836912B1/en active Active
  • 2019-08-15 CN CN201980051160.XA patent/CN112770736B/zh active Active
  • 2019-08-15 US US17/264,924 patent/US11896564B2/en active Active
  • 2019-08-15 JP JP2021506258A patent/JP7512251B2/ja active Active
  • 2019-08-15 MX MX2021001349A patent/MX2021001349A/es unknown
  • 2019-08-15 BR BR112021001984-7A patent/BR112021001984A2/pt not_active IP Right Cessation
  • 2019-08-15 AU AU2019322564A patent/AU2019322564A1/en not_active Abandoned
• 2021
  • 2021-02-01 IL IL280548A patent/IL280548A/en unknown

Patent Citations (9)

Non-Patent Citations (36)

Also Published As

Similar Documents

Legal Events